Rheumatoid Arthritis: Abatacept and Daratumumab Treatment

We are studying a combination of two medications to see if it is safe and effective for people with rheumatoid arthritis who have specific antibodies. This research aims to explore new ways to manage autoimmunity in these patients.

6-12 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesInjectionInternal MedicineRheumatology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Darzalex
Darzalex is a medicine used to treat multiple myeloma, a type of blood cancer.
Orencia
Orencia is a medicine used to treat rheumatoid arthritis and related conditions by helping reduce joint inflammation and pain.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Abatacept
Abatacept is a substance that reduces immune system overactivity to treat autoimmune conditions such as rheumatoid arthritis.
Daratumumab
Daratumumab is a substance that helps treat multiple myeloma, a blood cancer, by directing the immune system to attack the cancerous plasma cells.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Charite Universitaetsmedizin Berlin KöR
Department of Rheumatology and Clinical Immunology
Berlin, Germany
Universitaetsklinikum Erlangen AöR
Department of Medicine 3 - Rheumatology and Immunology
Erlangen, Germany
Sponsor: Charite Universitaetsmedizin Berlin KöR
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.